Nrgastro.2012.199
Upcoming SlideShare
Loading in...5
×
 

Nrgastro.2012.199

on

  • 191 views

 

Statistics

Views

Total Views
191
Views on SlideShare
191
Embed Views
0

Actions

Likes
0
Downloads
1
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Nrgastro.2012.199 Nrgastro.2012.199 Document Transcript

  • REVIEWS Medical therapies for hepatocellular carcinoma: a critical view of the evidence Augusto Villanueva, Virginia Hernandez-Gea and Josep M. Llovet Abstract | The management of hepatocellular carcinoma (HCC) has substantially changed in the past few decades. Improvements in patient stratification (for example, using the Barcelona Clinic Liver Cancer staging system) and the introduction of novel therapies (such as sorafenib) have improved patient survival. Nevertheless, HCC remains the third most common cause of cancer-related deaths worldwide. Decisionmaking largely relies on evidence-based criteria, as depicted in the US and European clinical practice guidelines, which endorse five therapeutic recommendations: resection; transplantation; radiofrequency ablation; chemoembolization; and sorafenib. However, areas still exist in which uncertainty precludes a strong recommendation, such as the role of adjuvant therapies after resection, radioembolization with yttrium‑90 or second-line therapies for advanced HCC. Many clinical trials that are currently ongoing aim to answer these questions. The first reported studies, however, failed to identify novel therapeutic alternatives (that is, sunitinib, erlotinib or brivanib). Moreover, genomic profiling has enabled patient classification on the basis of molecular parameters, and has facilitated the development of new effective drugs. However, no oncogene addiction loops have been identified so far, as has been the case with other cancers such as melanoma, lung or breast cancer. Efforts that focus on the implementation of personalized medicine approaches in HCC will probably dominate research in the next decade. Villanueva, A. et al. Nat. Rev. Gastroenterol. Hepatol. 10, 34–42 (2013); published online 13 November 2012; doi:10.1038/nrgastro.2012.199 Introduction Hepatocellular Carcinoma Translational Research Laboratory, Barcelona Clinic Liver Cancer Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Liver Unit, Hospital Clínic, Villarroel 170, Barcelona 08036, Catalonia, Spain (A. Villanueva, V. Hernandez-Gea, J. M. Llovet). Correspondence to: J. M. Llovet jmllovet@clinic.ub.es Disease burden owing to hepatocellular carcinoma (HCC) is increasing markedly worldwide.1 In the USA, epidemiological data published in 2009 show a substantial increase in HCC mortality in the past few decades2— a trend that underscores the importance of this disease in upcoming years.3 Nonetheless, major improvements have been made in HCC management during the past 30 years. Traditionally, HCC was considered a deadly disease without curative options, with an overall survival of <6  months. 4 Advances in early detection, imaging techniques and novel therapies have improved patient selection and enabled evidence-based treatment approaches.5 Consequently, prognostic algorithms, such as the Barcelona Clinic Liver Cancer (BCLC) classification, have been introduced in routine clinical care.4 The BCLC approach classifies patients according to tumour burden, underlying liver dysfunction and patient symptoms (Figure 1); it additionally links each stage to specific therapeutic interventions.5 The BCLC system is widely accepted, being currently endorsed by US and European associations for the study of liver diseases and oncology.5,6 Better patient selection has resulted in improvements in patient outcomes for almost every approved Competing interests J. M. Llovet declares associations with the following companies: Bayer Pharmaceutical, Biocompatibles, Bristol–Myers–Squibb, Imclone. See the article online for full details of the relationships. The other authors declare no competing interests. 34  |  JANUARY 2013  |  VOLUME 10 therapeutic intervention in HCC, including curative (for example, resection, transplantation, local ablation) and palliative (for example, transarterial chemoembolization [TACE]) approaches. In addition, the molecular-targeted agent sorafenib has shown antitumour activity in patients with advanced HCC, improving 3  months overall survival and delaying tumour progression.7 HCC frequently occurs in a damaged organ; liver cirrhosis owing to viral hepatitis (HBV or HCV infection) and alcohol abuse are the main risk factors. 8 However, the rapid development of potent antiviral agents and the increasing incidence of cirrhosis owing to NASH and overweight will modify the aetiological landscape of chronic liver disease in the next decades.9 The unique coexistence of two diseases—cirrhosis and HCC—in the same patient complicates the prognostic prediction and therapeutic strategies. This coexistence was observed in a phase III trial assessing sunitinib versus sorafenib in patients with advanced HCC, which was prematurely halted owing to toxicity and futility in the sunitinib arm.10 This finding emphasizes the fact that patients with cirrhosis, even at early stages of liver failure, are more susceptible to toxicities associated with drugs that are otherwise harmless in individuals without liver disease (sunitinib is approved for renal cell carcinoma). This issue, in addition to the fact that conventional chemotherapy was proven ineffective for this malignancy, 11 makes HCC management particularly challenging. This  www.nature.com/nrgastro © 2013 Macmillan Publishers Limited. All rights reserved
  • REVIEWS Review will dissect the evidence behind medical interventions in HCC, and discuss some relevant areas of controversy in disease management. Milestones in research and management Evidence-based approaches are progressively governing decision-making in medicine. This development is particularly relevant in oncology, in which the disease is frequently lethal and medical interventions can have major adverse effects. Hence, changes in the standard of care need to be supported by robust data. In fact, clinical practice guidelines tend to follow evidence-based criteria to select and grade clinical recommendations, as is the case for HCC.5 This approach enables the establishment of a hierarchy of recommendations based on levels of evidence, and identifies those ‘grey areas’ in which more research is required to provide clear recommendations. When considering HCC management, only five interventions reach the highest level of evidence, being worldwide accepted recommendations for the treatment of HCC:5 resection for patients with solitary tumours and well-preserved liver function; liver transplantation for patients with tumours within Milan criteria (single nodules <5 cm or three nodules <3 cm);12 percutaneous ablation with radiofrequency in early tumours not suitable for surgical treatment; TACE for patients with multinodular asymptomatic tumours without vascular invasion or extrahepatic spread (BCLC B); and sorafenib for patients at advanced stage (Figure 1). Beyond this framework, all other interventions require additional research to prove survival advantages when confronted with the above-mentioned standards of care. Such is the case for internal radioembolization with ytrrium-90 or the role of adjuvant therapies after resection.5 Herein, we discuss some of the areas of HCC management that require improvement and summarize the evidence currently available. The most relevant advances in HCC management have resulted from randomized studies, meta-analysis and cohort studies providing different levels of evidence and strength of recommendations in guidelines of clinical practice (Figure 2). Some of these pivotal studies have been widely cited, and represent scientific milestones in liver cancer research (Table 1); even though clinical decision-making should rely on recommendations based on levels of evidence, showing how frequently these recommendations reflect the importance of published research when evaluating the total number of citations is interesting. Table 1 summarizes the most relevant achievements and milestones in HCC research during the past 30 years, represented in hierarchical order according to number of citations and topic. These milestone studies in HCC address different aspects of clinical management such as epidemiology (association between viral hepatitis and HCC development), surgery (Milan criteria for liver transplantation, intention-totreat analysis for resection), locoregional therapies (percutaneous ablation in small tumours, randomized trials and meta-analyses of TACE), chemoprevention (HBV vaccination or interferon therapy and decreased Key points ■■ Epidemiological data indicate that the disease burden of hepatocellular carcinoma (HCC) is increasing worldwide, both in terms of incidence and mortality ■■ The Barcelona Clinic Liver Cancer staging system provides a general framework for decision-making in patients with HCC, and facilitates stage-based unified selection criteria for clinical trials ■■ Evidence-based criteria dominate recommendations for HCC management, enabling stratification of evidence according to scientific standards and providing a hierarchy of medical recommendations ■■ Five treatments are strongly recommended in HCC on the basis of evidencebased data: resection; liver transplantation; radiofrequency ablation; chemoembolization; and sorafenib ■■ Sorafenib, a molecular targeted agent, prolongs survival in patients with advanced HCC and is the sole systemic drug that is proved to be effective in this disease ■■ No oncogenic addiction loops have so far been identified in HCC; research initiatives should aim to identify subgroups of patients with targetable dominant molecular alterations HCC risk) and systemic therapies (such as sorafenib). Besides clinically oriented studies, few other studies represent true breakthroughs in the understanding of the pathogenesis of HCC, such as TP53 mutations and HCC in aflatoxin endemic areas, or the oncogenic role of HBV and core proteins in transgenic mice.13 With respect to HCC management, to date, the highest cited paper (Table 1; n = 2,331 citations) is the landmark study published in 1996 by Mazzaferro et al.12 that introduced the Milan criteria for selection of optimal HCC candidates for liver transplantation. When analysing the manuscripts according to number of citations per year, the sorafenib study ranks first with an average of 325 citations per year. Not surprisingly, both studies provide the rationale for strong clinical practice recommendations in HCC management.5,6 In fact, substantial overlap exists between findings from the top cited papers and the clinical recommendations made in guidelines.5 Breakthroughs in the management of human cancers have been dominated by the discovery and selective blockade of so-called oncogenic addiction loops.14,15 The concept of oncogene addiction describes the selective dependence of cancer cell proliferation to certain molecular aberrations. Tumoural cells become dependent on and/or addicted to a specific molecular alteration responsible for its own controlled proliferation.16 Many of these loops have been therapeutically exploited and some have substantially improved patient survival. 14 Examples include BRAF-mutated metastatic melanoma and response to vemurafenib,17 or ALK rearrangements in lung cancer and response to crizotinib.18 Strikingly, ALK oncogenic addiction in lung tumours was discovered after a fairly short timeframe: 3 years passed between the identification of ALK rearrangement 19 and publication of the phase II trial.18 Unfortunately, not a single oncogenic addiction loop has thus far been identified in HCC.15 However, several efforts aimed at improving patient selection for novel therapies in HCC, such as deep sequencing and genomic profiling,20 are ongoing and could elucidate oncogenic addiction loops in the setting of HCC. NATURE REVIEWS | GASTROENTEROLOGY & HEPATOLOGY © 2013 Macmillan Publishers Limited. All rights reserved VOLUME 10  |  JANUARY 2013  |  35
  • REVIEWS HCC Stage 0 PST 0, Child–Pugh A Stage A–C PST 0–2, Child–Pugh A–B Very early stage (0) Single <2 cm Carcinoma in situ Early stage (A) Single or 3 nodules ≤3 cm PST 0 Single Stage D PST >2, Child–Pugh C Intermediate stage (B) Multinodular PST 0 Advanced stage (C) Portal invasion N1, M1, PST 1–2 Terminal stage (D) TACE Sorafenib Best supportive care Target: 20% OS: 20 months (SD 14–45) Target: 40% OS: 11 months (SD 6–14) Target: 10% OS: <3 months 3 nodules ≤3 cm Portal pressure and/or bilirubin Increased Normal Resection Associated diseases No Liver transplantation (DDLT/LDLT) Yes RF/PEI Curative treatment (30–40%) Median OS >60 months; 5-year survival: 40–70% Figure 1 | BCLC staging system and therapeutic strategy according to EASL–EORTC guidelines. Staging classification comprises five stages that select the best candidates for the best therapies currently available. Patients with asymptomatic early tumours (stage 0–A) are candidates for radical therapies (resection, transplantation or local ablation). Asymptomatic patients with multinodular HCC (stage B) are suitable for chemoembolization (TACE), whereas patients with advanced symptomatic tumours and/or an invasive tumoural pattern (stage C) are candidates to receive sorafenib. End-stage disease (stage D) includes patients with grim prognosis that should be treated by best supportive care. Abbreviations: BCLC, Barcelona Clinic Liver Cancer; DDLT, deceased donor liver transplantation; EASL, European Association for the Study of Liver Disease; EORTC, European Organisation for Research and Treatment of Cancer; GRADE, grading of recommendations assessment, development and evaluation; HCC, hepatocellular carcinoma; LDLT, living donor liver transplantation; PEI, percutaneous ethanol injection; RF, radiofrequency ablation; TACE, transcatheter arterial chemoembolization; OS, overall survival; PST, performance status. Permission obtained from Elsevier © European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. J. Hepatol. 56, 908–943 (2012). Evidence-based management of HCC Chemoprevention Identification of patients at risk of HCC development has become a public health priority. Assuming that close to 1% of the global population has cirrhosis21 and one-third of patients develop HCC in their lifespan,5 the expected number of lives saved following successful prevention of HCC is substantial. Cirrhosis of any aetiology is, by itself, a risk factor for the development of HCC.22 In terms of primary prevention, studies from Taiwan clearly demonstrated that prevention of HBVrelated liver disease with universal vaccination is highly effective at diminishing HCC rates. 23 Consequently, since 1991, the WHO has recommended vaccination of all newborn babies and high-risk individuals.24 In the setting of chronic hepatitis B or C, the main risk factors for the development of HCC are the presence of advanced hepatic fibrosis or cirrhosis, and high viral load.25 In fact, current guidelines recommend antiviral treatment to suppress virus replication and prevent the progression of fibrosis.26 Few randomized controlled trials (RCTs) are available that evaluate the role of HBV treatment for HCC prevention as a primary end point. The only two RCTs designed to measure the importance 36  |  JANUARY 2013  |  VOLUME 10 of treatment on HCC development showed that both interferon27 and lamivudine28 are effective in increasing HBV clearance, decreasing cirrhosis progression and subsequently reducing HCC risk. Studies with PEGIFN‑α are limited and restricted to the demonstration of improvement of surrogate markers (for example, viral DNA suppression, hepatitis B e antigen sero­ onversion c and hepatitis B surface antigen loss),29 although the clinical benefits are expected to be at least similar to those with conventional IFN‑α. Regarding chronic HCV infection, achievement of sustained virologic response has been shown to decrease the risk of HCC in patients with chronic hepatitis C.30 However, once cirrhosis is established, the benefit of antiviral treatment for HCV infection in terms of HCC prevention remains unclear.31 Moreover, maintenance treatment in nonresponders with IFN‑α was neither beneficial for fibrosis progression nor for HCC development.32 As previously mentioned, the vast majority of HCC occurs in cirrhotic livers and increasing evidence suggests that fibrosis per se confers carcinogenic risk.33 Molecular data also point towards a major pathogenic role for diseased liver microenvironment (‘field effect’) in HCC development.34 Hence, reversal of fibrosis regardless  www.nature.com/nrgastro © 2013 Macmillan Publishers Limited. All rights reserved
  • REVIEWS Treatment Stage-oriented HCC management based on the BCLC algorithm (Figure 1) classifies medical interventions as potentially curative (for example, surgical resection, liver transplantation or percutaneous ablation) or palliative (for example, TACE and sorafenib).5 Treatment allocation is based on levels of evidence as defined by the National Cancer Institute, which rely on strengths of study design and end points. Herein, we summarized the different therapeutic interventions for HCC according to these evidence-based parameters (Figure 2). Surgical treatments Surgical resection and liver transplantation are first-line options for patients with early stage HCC (BCLC)0–A), as they confer 5‑year survival rates of 70%.39 Improvements in surgical approaches and refined selection of candidates for surgery (single nodule without liver dysfunction of portal hypertension40) have contributed to increased patient survival, minimization of complications and reduced recurrence.41 Overall, recurrence after resection reaches 70% at 5 years, either because of true metastases or de novo HCC,42 and no adjuvant therapies able to reduce recurrence are currently approved. Local ablation has been suggested as a competitive alternative to resection in patients with a single tumour <2 cm.43 As no RCT has been designed ad hoc to address this issue, the role of local ablation as a first-line option in this setting remains controversial. Patients within Milan criteria (that is, single tumour <5 cm or three nodules <3 cm), without vascular invasion (BCLC A) should be evaluated for liver transplantation.5 These criteria have Sorafenib 1 Levels of evidence of primary aetiology could theoretically prevent HCC development. However, studies targeting fibrosis as a chemopreventive strategy are scarce. Only two large, prospective, placebo-controlled studies have tested antifibrotic agents and showed no effects on fibrosis after 1 year of therapy.35,36 Overall, besides primary prevention efforts aimed at avoiding known environmental risks for liver disease (including, HBV vaccination and withdrawal of alcohol intake), or antiviral therapy to suppress viral load in chronic hepatitis, no clear measures to decrease HCC incidence in patients with cirrhosis are available. In addition, little is known about the predictors that confer higher risk among individuals with cirrhosis, which justifies the recommendation of surveillance with abdominal ultrasonography every 6 months in all patients with cirrhosis.5 Preliminary evidence at the molecular level in experimental studies has identified different signalling pathways as potential targets for chemoprevention (for example, EGFR and PDGFR37,38). However, there are two major drawbacks to developing effective drugs in the chemoprevention setting: first, the expected long duration of these trials requires the inclusion of enrichment strategies to increase feasibility by selecting those patients at very high risk of HCC development; second, a pressing need exists to identify accurate and non­ nvasive biomarkers for diagnosis and i monitoring of fibrosis progression. Chemoembolization Adjuvant therapy after resection RF (<5 cm), RF and/or PEI (<2 cm) Resection LDLT Internal radiation OLT-extended Neoadjuvant therapy in waiting list 2 OLT-Milan Downstaging 3 External and/or palliative radiotherapy C B A C 2 (weak) B A 1 (strong) Grade of recommendation Figure 2 | Therapeutic interventions in HCC according to level of evidence and grade of recommendation. Level of evidence (based on NCI classification and grade of recommendation based on GRADE criteria. Abbreviations: GRADE, grading of recommendations assessment, development and evaluation; HCC, hepatocellular carcinoma; LDLT, living donor liver transplantation; OLT, orthotopic liver transplantation; NCI, National Cancer Institute; PEI, percutaneous ethanol injection; RF, radiofrequency ablation. Permission obtained from Elsevier © European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. J. Hepatol. 56, 908–943 (2012). been independently validated by several groups and are widely adopted in transplant centres in Europe and the USA.39 Despite their utility, Milan criteria might be too restrictive and preliminary evidence indicates that some patients with tumours exceeding Milan criteria are potentially curable by liver transplantation.44,45 Studies using clinical or pathological variables to expand Milan criteria have a number of methodological limitations, such as small sample size46 and their retrospective nature,47 which prevents providing any recommendation owing to lack of robust data. A retrospective study suggested that microvascular invasion was a limiting factor to discriminate good and poor outcome among patients with HCC who underwent liver transplantation within and beyond Milan criteria (under the so-called up-toseven rule).45 These data emphasize the need to unravel molecular readouts of tumour biology to enable proper decision-making.48 Locoregional therapies Local ablation is the standard of care for patients with early stage tumours who are not suitable for surgery; survival rates are 50–70% at 5 years with this approach.5 Radiofrequency is the first option, and percutaneous ethanol injection is only reserved as a complementary treatment in cases of difficult tumour location.5 Patients with multinodular disease, preserved liver function, without tumour-related symptoms and absence of vascular invasion or extrahepatic spread (BCLC B, intermediate stage) are candidates for TACE, with the goal of delaying tumour progression and extension of patient survival.5,6 Evidence to support this recommendation comes from a meta-analysis of pooled data.11 Improvements in embolization devices (for example, drug-eluting beads) provide median survival rates NATURE REVIEWS | GASTROENTEROLOGY & HEPATOLOGY © 2013 Macmillan Publishers Limited. All rights reserved VOLUME 10  |  JANUARY 2013  |  37
  • REVIEWS Table 1 | Milestones in HCC research reported during the past 30 years* Citations Reference Title Thematic area Direct influence on CPG Citations per year Molecular pathogenesis 1,640 Knowles et al. (1980)83 Human HCC cell lines secrete the major plasma proteins and hepatitis B surface antigen Basic science No 49 1,285 Hsu et al. (1991)84 Mutational hotspot in the p53 gene in human HCCs Basic science No 56 1,085 Bressac et al. (1991)85 Selective G‑mutation to T‑mutation of p53 gene in HCC from Southern Africa Basic science No 48 788 Kim et al. (1991)86 HBx gene of HBV induces liver cancer in transgenic mice Basic science No 34 736 Moriya et al. (1998)87 The core protein of HCV induces HCC in transgenic mice Basic science No 46 Epidemiology and natural history 1,867 Beasley et al. (1981)88 HCC and HBV: a prospective study of 22,707 men in Taiwan Epidemiology No 57 1,661 El-Serag et al. (1999)89 Rising incidence of HCC in the US Epidemiology No 116 1,215 Okuda et al. (1985) Natural history of HCC and prognosis in relation to treatment: study of 850 patients Prognosis No 42 978 Kiyosawa et al. (1990)91 Interrelationship of blood transfusion, non‑A, non‑B hepatitis and HCC: analysis by detection of antibody to HCV Epidemiology No 42 943 Saito et al. (1990)92 HCV infection is associated with the development of HCC Epidemiology No 40 881 Chang et al. (1997)23 Universal HBV vaccination in Taiwan and the incidence of HCC in children Chemoprevention Yes 54 899 Chen et al. (2006)25 Risk of HCC across a biological gradient of serum HBV DNA level Epidemiology No 118 720 Tsukuma et al. (1993)93 Risk factors for HCC among patients with chronic liver disease Epidemiology No 35 683 Nishiguchi et al. (1995) Randomized trial of effects of IFN-α on incidence of HCC in chronic active hepatitis C with cirrhosis Chemoprevention No 37 668 Bruix et al. (1989)95 Prevalence of antibodies to HCV in Spanish patients with HCC and hepatic cirrhosis Epidemiology No 28 2,331 Mazzaferro et al. (1996)12 Liver transplantation for the treatment of small HCC in patients with cirrhosis Surgery Yes 129 1,777 Llovet et al. (2008)7 Sorafenib in advanced HCC Systemic therapy Yes 325 984 Llovet et al. (2002) Arterial embolization or chemoembolization vs symptomatic treatment in patients with unresectable HCC: a randomized controlled trial Locoregional Yes 84 831 Llovet et al. (2003)11 Systematic review of randomized trials for unresectable HCC: chemoembolization improves survival Locoregional Yes 78 791 Livraghi et al. (1999)97 Small HCC: treatment with radiofrequency ablation vs ethanol injection Locoregional Yes 56 791 Lo et al. (2002)98 Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable HCC Locoregional Yes 59 722 Llovet et al. (1999)99 Intention-to-treat analysis of surgical treatment for early HCC: resection vs transplantation Surgery Yes 50 730 Curley et al. (1999)100 Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients Locoregional No  49 663 Livraghi et al. (1995)101 HCC and cirrhosis in 146 patients: long-term results of percutaneous ethanol injection Locoregional Yes 36 90 94 Treatment 96 Data accessed on Web of Science®(Thomson Reuters, New York, USA), using the search terms “hepatocellular carcinoma” or “liver cancer” on 20 September 2012. *Sorted by number of citations. Abbreviations: CPG, clinical practice guidelines; HCC, hepatocellular carcinoma. beyond 30–40 months, at least in referral centres. 49 Findings from a Cochrane Review have challenged the role of TACE as the standard of care for patients with intermediate stage HCC,50 but the inclusion of studies using inadequate control arms and suboptimal patient selection might bias this conclusion.51 Regarding other embolization approaches (such as radioembolization with microspheres loaded with yttrium‑90), data suggest 38  |  JANUARY 2013  |  VOLUME 10 it has a favourable safety profile,52 but only well-designed, properly powered RCTs will determine the therapeutic niche, if any, of this intervention. Systemic therapies Until 2007, and despite substantial efforts, no single systemic agent had shown survival benefits in patients with HCC. This finding can be partially explained by  www.nature.com/nrgastro © 2013 Macmillan Publishers Limited. All rights reserved
  • REVIEWS the frequent coexistence of HCC and cirrhosis, its high molecular heterogeneity and a relative resistance to conventional chemotherapy.53 The SHARP trial demonstrated that sorafenib, a tyrosine kinase inhibitor with a broad inhibitory profile (for example, BRAF, PDGFR and VEGFR), was able to substantially increase survival in patients with advanced HCC (stage C of the BCLC classification: patients with well-preserved liver function and extrahepatic spread or vascular invasion) from 7.9 months to 10.7 months (HR 0.69).5,6 The effects of sorafenib in delaying tumour progression and improving survival were further validated in Asian HBV-infected patients.54 Adverse events such as diarrhoea or hand–foot skin reaction associated with sorafenib were manageable. On the basis of these data, sorafenib (400 mg, twice daily) is the standard of care for patients at advanced stages of HCC, and it should be maintained at least until radiological progression with periodic monitoring of adverse effects (mostly cardiovascular, diarrhoea and skin reactions).15 Thus far, no strong biomarkers are available to accurately predict a patient’s response to sorafenib.50 Numerous targeted therapies are currently under evaluation in different developmental phases for the systemic treatment of HCC, both as first and second-line therapies (thoroughly reviewed elsewhere15). Regarding potential registration trials, initial results have been negative: the sunitinib trial was prematurely halted because of adverse events and futility in the sunitinib arm as a firstline therapy. Brivanib showed an antitumoural effect that did not markedly improve survival compared with placebo in second-line therapies,55 and the phase III trial testing the multikinase inhibitor linifanib has therefore been halted.56 Furthermore, the combination of sorafenib and EGFR inhibitors (erlotinib) failed in comparison to sorafenib alone as a first-line therapy.57 The remaining ongoing phase III trials are testing monoclonal anti­ bodies against VEGFR2 (ramucirumab) and mTOR (mammalian target of rapamycin) inhibitor (everolimus). In addition, >250 early phase clinical trials of HCC therapies are ongoing, testing 56 molecular therapies.15 If more trial results are negative, alternative approaches will be needed to improve on the results already achieved with sorafenib. Potential alternatives are, first, the identification of drugs that can be safely used in combination with sorafenib. Second, the discovery of oncogene addiction loops that restrict survival benefits in a subpopulation of patients with HCC (for example, MET-positive patients), and third, to develop drugs targeting novel signalling cascades (for example, WNT–β-catenin and Notch) or molecular mechanisms (for example, epigenetic aberrations). In any case, it will be necessary to implement changes to the current paradigm of trial design (Box 1). Progressively, enrolment criteria should include mol­ ecular information of the mechanisms responsible for tumour progression in each patient, following previous examples in other solid tumours.58 Adjuvant therapies as a first unmet need Tumour recurrence is a major complication after resection, occurring in 70% of patients at 5 years after Box 1 | Main issues for phase II/III trial design in patients with HCC102,103 To select the target population ■■ BCLC stage: include patients at specific BCLC stage (A–C) ■■ Child–Pugh classification: include Child–Pugh A To choose the appropriate end points ■■ Overall survival (main end point in cancer research) ■■ Time to progression* ■■ Objective response rate* To decide the adequate control arm ■■ TACE for intermediate stage ■■ Sorafenib for advanced stage (first-line therapy) ■■ Placebo plus best supportive care for advanced stages (second-line therapy) To stratify factors before randomization ■■ ECOG performance status ■■ Tumour burden (extrahepatic spread and/or vascular invasion) ■■ AFP levels >200 ng/ml *Time to progression and overall response rate should be assessed according to modified RECIST criteria. Abbreviations: AFP α-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; ECOG, , Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; OS, overall survival; RECIST, response evaluation criteria in solid tumours; TACE, transarterial chemoembolization. surgery. 39 Unlike most malignancies, two clear patterns of recurrence exist in HCC. Early recurrences (<2 years) are related to early dissemination of the primary tumour (that is, true metastasis) whereas late recurrences (>2 years) are a result of the carcinogenic cirrhotic milieu present in the remaining liver that promotes the progression of new malignant clones (that is, de novo tumours).42,59 Feasibly, each type might have a different molecular background and therefore would require different therapeutic approaches for its prevention.60 Unfortunately, despite the fact that several RCTs have been conducted to evaluate adjuvant therapy, no agent has shown robust efficacy in preventing or delaying tumour recurrence.5 The role of IFN‑α as adjuvant therapy after resection has been frequently evaluated in different studies, including RCTs.61,62 One of the largest trials analysed the use of IFN‑α in 150 patients with HCC, finding a negative trend for the primary end point (recurrence-free survival), but a positive trend in terms of prevention of late recurrence of HCC in the patients tested.63 Additionally, different meta-analyses have tried to provide a more comprehensive answer for the role of IFN‑α in preventing HCC recurrence.64–66 Owing to conflicting data and issues related to study design (such as trial selection for metaanalysis and mixing end points), IFN‑α is currently not recommended as an adjuvant therapy after resection.5 In HBV-related HCC, a systematic review including 230 patients with HCC treated with ablation or resection found no evidence to support the use lamivudine with or without adefovir as adjuvant therapy.67 Besides IFN‑α, other agents such as vitamin analogues have been evaluated in the adjuvant setting. Vitamin K was believed to have a beneficial effect in prolonging disease-free survival on the basis of findings from small studies.68–70 However, when tested in a large RCT including >500 patients, vitamin K was unable to prevent either HCC recurrence or death.71 Vitamin A analogues also have controversial results. Although the acyclic NATURE REVIEWS | GASTROENTEROLOGY & HEPATOLOGY © 2013 Macmillan Publishers Limited. All rights reserved VOLUME 10  |  JANUARY 2013  |  39
  • REVIEWS retinoid prevented the development of secondary HCC after resection and improved survival in one RCT, 72 this result was not validated in an, as yet unpublished, large, multicentre RCT.73 Regarding adoptive immunotherapy with IL‑2-activated lymphocytes, despite initial encouraging results,74 this strategy has not been subsequently validated and it is not recommended in HCC clinical management.5 Also, no survival benefits have been established with other immunotherapy regimens including cytokine-induced killer cells.75 Currently, two large phase III RCTs are ongoing that are evaluating the role of sorafenib and rapamycin in preventing tumour recurrence after resection and/or ablation (STORM trial)76 and after liver transplantation (SiLVER trial)77 in patients with HCC. One of the main limitations of liver transplantation for HCC is donor shortage, which causes longer waiting times and increases drop-out rates as a result of tumour progression whilst waiting for a graft. Therefore, transplant groups are applying locoregional therapies upon listing to prevent drop out. 78 Evidence behind this approach comes from uncontrolled studies and cost– benefit analysis,78 showing that when expected waiting time exceeds 6 months it is cost-effective to offer the patient neoadjuvant therapies. This approach has been incorporated in a consensus document on HCC and liver transplantation that recommends locoregional therapies in patients with HCC within Milan criteria or United Network for Organ Sharing stage T2 (one nodule 2–5 cm or ≤3 nodules each ≤3 cm), with an expected waiting time longer than 6 months.5,79 Medical therapies, including sorafenib, have not been able to demonstrate a beneficial effect in this particular setting. Towards molecular medicine in HCC The future paradigm for treating patients with HCC includes customization of medical interventions on the basis of molecular alterations that govern tumour develop­ ent and progression on an individual basis. m In this regard, the most straightforward approach is to identify and validate oncogenic addiction loops, following the path opened in other solid tumours (for example, mutated BRAF melanoma, ALK rearrangements in lung cancer, and so on). Deep analysis of the HCC genome (such as exome and RNA sequencing) could provide new candidates. Several failures of systemic treatment in firstline therapy (brivanib versus placebo,80 sorafenib plus erlotinib versus sorafenib,81 sorafenib versus linifanib56 and sorafenib versus sunitinib)82 and second-line therapy 1. 2. 3. 4. Altekruse, S. F., McGlynn, K. A. & Reichman, M. E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol. 27, 1485–1491 (2009). Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009). El-Serag, H. B. Hepatocellular carcinoma. N. Engl. J. Med. 365, 1118–1127 (2011). Llovet, J. M., Bru, C. & Bruix, J. Prognosis of hepatocellular carcinoma: the BCLC staging 40  |  JANUARY 2013  |  VOLUME 10 5. 6. (brivanib versus placebo)55 alert us to several concerns: the heterogeneity of the disease; toxicity of multikinase inhibitors in patients with cirrhosis; complexity of the disease; and the need for a more stratified approach by using reliable biomarkers and drugs for specific mol­ ecular aberrations. Targeting oncogenic addiction loops is expected to add survival benefits to the existing HCC therapy that currently relies on sorafenib. Besides trial enrichment, combination therapies can also improve the current standard of care. The wide inhibitory profile of sorafenib, in addition to an anti­ angiogenic effect and good safety profile confirms this drug as the benchmark for systemic management of HCC. The bottleneck of the combination approach will be drug toxicity. The trade-off between efficacy and adverse effects is pivotal in this scenario, as patients with cirrhosis are clearly more susceptible to adverse effects of drugs than patients without cirrhosis. When considering changing the standard of care for HCC management, any intervention should be evaluated in the context of well-designed, properly powered, high-level RCTs—only these types of studies can currently change accepted treatment recommendations in guidelines. Conclusions The management of HCC has changed substantially in the past few decades, and five treatment options are accepted in clinical guidelines. Decision-making relies on evidence-based criteria; however, despite the recent advance in the understanding of HCC patho­ hysiology p and development of new therapies, several clinical areas lack strong recommendations. The approval of sorafenib changed the understanding of HCC and brought in a new era in the management of liver cancer, led by the effort in understanding the molecular regulation and the identification of new molecular targets. Efforts on the implementation of personalized medicine will probably dominate research in the next decade. Review criteria A search for original articles focusing on hepatocellular carcinoma was performed in MEDLINE and PubMed. The search terms used were “hepatocellular carcinoma”, “liver cancer”, “treatment”, “management”, “medical therapies”, “randomized” and “systemic review”, alone and in combination. All articles identified were Englishlanguage, full-text papers. We also searched the reference lists of identified articles for further relevant papers. classification. Semin. Liver Dis. 19, 329–338 (1999). European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908–943 (2012). Bruix, J. & Sherman, M. Management of hepatocellular carcinoma: an update. Hepatology 53, 1020–1022 (2011).  7. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008). 8. Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245–1255 (2012). 9. Ascha, M. S. et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51, 1972–1978 (2010). 10. Cheng, A. et al. Phase III trial of sunitinib versus sorafenib in advanced hepatocellular carcinoma www.nature.com/nrgastro © 2013 Macmillan Publishers Limited. All rights reserved
  • REVIEWS 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. [abstract 4000]. J. Clin. Oncol. 29 (Suppl.), 4000 (2011). Llovet, J. M. & Bruix, J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37, 429–442 (2003). Mazzaferro, V. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334, 693–699 (1996). Hsu, I. C. et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350, 427–428 (1991). Dancey, J. E., Bedard, P . L., Onetto, N. & Hudson, T. J. The genetic basis for cancer treatment decisions. Cell 148, 409–420 (2012). Villanueva, A. & Llovet, J. M. Targeted therapies for hepatocellular carcinoma. Gastroenterology 140, 1410–1426 (2011). Weinstein, I. B. Cancer. Addiction to oncogenes—the Achilles heal of cancer. Science 297, 63–64 (2002). Chapman, P et al. Improved survival with . B. vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011). Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non‑small‑cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2010). Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non‑small‑cell lung cancer. Nature 448, 561–566 (2007). Zender, L. et al. Cancer gene discovery in hepatocellular carcinoma. J. Hepatol. 52, 921–929 (2010). Schuppan, D. & Afdhal, N. H. Liver cirrhosis. Lancet 371, 838–851 (2008). Ioannou, G. N. et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 5, 938–945 (2007). Chang, M. H. et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 336, 1855–1859 (1997). [No authors listed] Expanded programme on immunization. Global Advisory Group—Part II. Wkly Epidemiol. Rec. 67, 17–19 (1992). Chen, C. J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295, 65–73 (2006). Lok, A. S. & McMahon, B. J. Chronic hepatitis B: update 2009. Hepatology 50, 661–662 (2009). Lin, S. M., Sheen, I. S., Chien, R. N., Chu, C. M. & Liaw, Y. F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29, 971–975 (1999). Liaw, Y. F. et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351, 1521–1531 (2004). Marcellin, P et al. Peginterferon α-2a alone, . lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351, 1206–1217 (2004). Singal, A. G., Volk, M. L., Jensen, D., Di Bisceglie, A. M. & Schoenfeld, P . S. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin. Gastroenterol. Hepatol. 8, 280–288 (2010). Di Bisceglie, A. M. et al. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 53, 1100–1108 (2011). 32. Bruix, J. et al. Maintenance therapy with peginterferon α-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 140, 1990–1999 (2011). 33. Zhang, D. Y. & Friedman, S. L. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 56, 769–775 (2012). 34. Hoshida, Y. et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359, 1995–2004 (2008). 35. Pockros, P et al. Final results of a double-blind, . J. placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology 45, 569–578 (2007). 36. McHutchison, J. et al. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology 138, 1365–1373 (2010). 37. Tanabe, K. K. et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 299, 53–60 (2008). 38. Mejias, M. et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 49, 1245–1256 (2009). 39. Llovet, J. M., Schwartz, M. & Mazzaferro, V. Resection and liver transplantation for hepatocellular carcinoma. Semin. Liver Dis. 25, 181–200 (2005). 40. Bruix, J. et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 111, 1018–1022 (1996). 41. Ishizawa, T. et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 134, 1908–1916 (2008). 42. Imamura, H. et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J. Hepatol. 38, 200–207 (2003). 43. Livraghi, T. et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 47, 82–89 (2008). 44. Roayaie, S. et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann. Surg. 235, 533–539 (2002). 45. Mazzaferro, V. et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 10, 35–43 (2009). 46. Yao, F. Y. et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33, 1394–1403 (2001). 47. Forner, A. & Bruix, J. To expand or not to expand the criteria for hepatocellular carcinoma transplantation: is downstaging the answer? Gastroenterology 137, 375–376 (2009). 48. Llovet, J. M., Paradis, V., Kudo, M. & ZucmanRossi, J. Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transpl. 17 (Suppl. 2), S67–S71 (2011). 49. Burrel, M. et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J. Hepatol. 56, 1330–1335 (2012). NATURE REVIEWS | GASTROENTEROLOGY & HEPATOLOGY © 2013 Macmillan Publishers Limited. All rights reserved 50. Oliveri, R. S., Wetterslev, J. & Gluud, C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst. Rev. Issue 1, Art. No.: CD004787. http://dx.doi.org/10.1002/ 14651858. 51. Forner, A., Llovet, J. M. & Bruix, J. Chemoembolization for intermediate HCC: is there proof of survival benefit? J. Hepatol. 56, 984–986 (2012). 52. Salem, R. et al. Radioembolization results in longer time‑to‑progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140, 497–507 e492 (2011). 53. Yeo, W. et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl Cancer Inst. 97, 1532–1538 (2005). 54. Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol. 10, 25–34 (2009). 55. Llovet, J. M. et al. Brivanib versus placebo in patients with advanced hepatocellular carcinoma who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS study. J. Hepatol. 56, S549 (2012). 56. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/ NCT01009593 (2012). 57. Bayer Investor Relations. Phase III trial evaluating the addition of tarceva®(erlotinib) to nexavar®(sorafenib) did not provide additional benefit to patients with liver cancer versus nexavar alone. Bayer [online], http://www. investor.bayer.de/user_upload/4112 (2012). 58. Kim, E. S. et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 1, 44–53 (2011). 59. Hoshida, Y. et al. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin. Liver Dis. 30, 35–51 (2010). 60. Villanueva, A. et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 140, 1501–1512 e1502 (2011). 61. Breitenstein, S. et al. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br. J. Surg. 96, 975–981 (2009). 62. Miao, R. Y. et al. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J. Gastroenterol 16, 2931–2942 (2010). 63. Mazzaferro, V. et al. Prevention of hepatocellular carcinoma recurrence with α-interferon after liver resection in HCV cirrhosis. Hepatology 44, 1543–1554 (2006). 64. Miyake, Y., Takaki, A., Iwasaki, Y. & Yamamoto, K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J. Viral Hepat. 17, 287–292 (2010). 65. Singal, A. K., Freeman, D. H. Jr & Anand, B. S. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment. Pharmacol. Ther. 32, 851–858 (2010). 66. Shen, Y. C. et al. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J. Hepatol. 52, 889–894 (2010). VOLUME 10  |  JANUARY 2013  |  41
  • REVIEWS 67. Zhong, J. H., Li, L. Q. & Wu, L. C. Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma. Cochrane Database Syst. Rev. Issue 12, Art. No.: CD008713. http:// dx.doi.org/10.1002/14651858.CD008713. pub2. 68. Hotta, N. et al. Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma. Hepatogastroenterology 54, 2073–2077 (2007). 69. Mizuta, T. et al. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 106, 867–872 (2006). 70. Kakizaki, S. et al. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J. Gastroenterol. Hepatol. 22, 518–522 (2007). 71. Yoshida, H. et al. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology 54, 532–540 (2011). 72. Muto, Y. et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N. Engl. J. Med. 334, 1561–1567 (1996). 73. Okita, K. et al. Peretinoin reduces recurrence of hepatocellular carcinoma: Results of a phase II/ III randomized placebo-controlled trial [abstract 4024]. J. Clin. Oncol. 28 (Suppl.), 15s (2010). 74. Takayama, T. et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 28, 1241–1246 (1998). 75. Hui, D., Qiang, L., Jian, W., Ti, Z. & Da-Lu, K. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig. Liver Dis. 41, 36–41 (2009). 76. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/ NCT00692770 (2012). 77. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/ NCT00355862 (2011). 78. Llovet, J. M. et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 50, 123–128 (2002). 42  |  JANUARY 2013  |  VOLUME 10 79. Clavien, P et al. Recommendations for liver . A. transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 13, e11–22 (2012). 80. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/ NCT00858871 (2012). 81. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/ NCT00901901 (2012). 82. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/ NCT00699374 (2012). 83. Knowles, B. B., Howe, C. C. & Aden, D. P Human . hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209, 497–499 (1980). 84. Hsu, I. C. et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350, 427–428 (1991). 85. Bressac, B., Kew, M., Wands, J. & Ozturk, M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350, 429–431 (1991). 86. Kim, C. M., Koike, K., Saito, I., Miyamura, T. & Jay, G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351, 317–320 (1991). 87. Moriya, K. et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 4, 1065–1067 (1998). 88. Beasley, R. P Hwang, L. Y., Lin, C. C. & ., Chien, C. S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 2, 1129–1133 (1981). 89. El-Serag, H. B. & Mason, A. C. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340, 745–750 (1999). 90. Okuda, K. et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56, 918–928 (1985). 91. Kiyosawa, K. et al. Interrelationship of blood transfusion, non‑A, non‑B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12, 671–675 (1990). 92. Saito, I. et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc. Natl Acad. Sci. USA 87, 6547–6549 (1990).  93. Tsukuma, H. et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J. Med. 328, 1797–1801 (1993). 94. Nishiguchi, S. et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346, 1051–1055 (1995). 95. Bruix, J. et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 2, 1004–1006 (1989). 96. Llovet, J. M. et al. Arterial emobolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 359, 1734–1739 (2002). 97. Livraghi, T. et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210, 655–661 (1999). 98. Lo, C. M. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35, 1164–1171 (2002). 99. Llovet, J. M., Fuster, J. & Bruix, J. Intention‑to‑treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30, 1434–1440 (1999). 100. Curley, S. A. et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann. Surg. 230, 1–8 (1999). 101. Livraghi, T. et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 197, 101–108 (1995). 102. Llovet, J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 100, 698–711 (2008). 103. Lencioni, R. & Llovet, J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30, 52–60 (2010). Author contributions All authors contributed equally to all aspects of this manuscript. www.nature.com/nrgastro © 2013 Macmillan Publishers Limited. All rights reserved